182 related articles for article (PubMed ID: 35190971)
1. Systemic Therapy for Chondrosarcoma.
Rock A; Ali S; Chow WA
Curr Treat Options Oncol; 2022 Feb; 23(2):199-209. PubMed ID: 35190971
[TBL] [Abstract][Full Text] [Related]
2. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.
Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Tap WD; Villalobos VM; Cote GM; Burris H; Janku F; Mir O; Beeram M; Wagner AJ; Jiang L; Wu B; Choe S; Yen K; Gliser C; Fan B; Agresta S; Pandya SS; Trent JC
J Clin Oncol; 2020 May; 38(15):1693-1701. PubMed ID: 32208957
[TBL] [Abstract][Full Text] [Related]
5. Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis.
Cranmer LD; Chau B; Mantilla JG; Loggers ET; Pollack SM; Kim TS; Kim EY; Kane GM; Thompson MJ; Harwood JL; Wagner MJ
Clin Orthop Relat Res; 2022 Apr; 480(4):748-758. PubMed ID: 34648466
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.
Jones RL; Katz D; Loggers ET; Davidson D; Rodler ET; Pollack SM
Med Oncol; 2017 Aug; 34(10):167. PubMed ID: 28852958
[TBL] [Abstract][Full Text] [Related]
7. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
9. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract][Full Text] [Related]
12. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
13. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.
Chow W; Frankel P; Ruel C; Araujo DM; Milhem M; Okuno S; Hartner L; Undevia S; Staddon A
Cancer; 2020 Jan; 126(1):105-111. PubMed ID: 31509242
[TBL] [Abstract][Full Text] [Related]
14. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.
van Maldegem A; Conley AP; Rutkowski P; Patel SR; Lugowska I; Desar IME; Bovée JVMG; Gelderblom H
Oncologist; 2019 Jan; 24(1):110-116. PubMed ID: 30082492
[TBL] [Abstract][Full Text] [Related]
15. The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan.
Nagano A; Tsugita M; Nishimoto Y; Akiyama H; Kawai A
Jpn J Clin Oncol; 2021 Aug; 51(9):1430-1436. PubMed ID: 34105731
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic diagnosis of de-differentiated chondrosarcoma].
Huang J; Zhang HZ; Zheng L; Zhou J; Jiang ZM
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):820-3. PubMed ID: 20193457
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas.
Bernstein-Molho R; Kollender Y; Issakov J; Bickels J; Dadia S; Flusser G; Meller I; Sagi-Eisenberg R; Merimsky O
Cancer Chemother Pharmacol; 2012 Dec; 70(6):855-60. PubMed ID: 23053256
[TBL] [Abstract][Full Text] [Related]
18. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
de Andrea CE; San-Julian M; Bovée JVMG
Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
[TBL] [Abstract][Full Text] [Related]
19. Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors.
Kushlinskii NE; Alferov AA; Timofeev YS; Gershtein ES; Bulycheva IV; Bondarev AV; Shchupak MY; Sokolov NY; Polikarpova SB; Efimova MM; Dzampaev AA; Sushentsov EA; Aliev MD; Musaev ER
Bull Exp Biol Med; 2020 Nov; 170(1):64-68. PubMed ID: 33231796
[TBL] [Abstract][Full Text] [Related]
20. Aberrant DNA methylations in chondrosarcoma.
Liu P; Shen JK; Xu J; Trahan CA; Hornicek FJ; Duan Z
Epigenomics; 2016 Nov; 8(11):1519-1525. PubMed ID: 27686001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
